Electromed, Inc. Form 10-K Summary
Reporting period: The provided filing is the annual report for the fiscal year ended June 30, 2014, compared with fiscal 2013. The request metadata references “2013 Q4,” but the filing is a full-year 2014 Form 10-K, not a quarterly filing.
Business Context
Electromed designs, manufactures and sells SmartVest high-frequency chest wall oscillation airway-clearance systems for patients with compromised pulmonary function. Sales are primarily to domestic home-care patients, with additional government, institutional and international sales. The SmartVest SQL was FDA-cleared in December 2013 and launched in the domestic home-care market during the second half of fiscal 2014.
Key Financial Metrics
| Metric | FY2014 | FY2013 | Change |
|---|---|---|---|
| Net revenue | $15.488 million | $15.104 million | Up 2.5% |
| Gross profit | $10.634 million | $10.449 million | Up $185,000 |
| Gross margin | 68.7% | 69.2% | Down 0.5 percentage points |
| Operating loss | $741,000 | $1.827 million | Improved $1.087 million |
| Net loss | $1.289 million | $1.329 million | Improved $41,000 |
| Loss per share | $0.16 | $0.16 | No change |
| Cash provided by operations | $2.063 million | $1.877 million | Up $186,000 |
| Capital expenditures | $895,000 | $1.017 million | Down $121,000 |
- Home-care revenue increased 1.0% to $12.997 million; government and institutional revenue increased 18.2% to $1.690 million; international revenue declined 1.4% to $801,000 and represented approximately 5.2% of net revenue.
- SG&A expense declined 6.5% to $10.909 million, while research and development expense declined to $466,000, or 3.0% of revenue.
- The company generated an operating profit of $362,000 in the fourth quarter after reducing operating losses in each preceding quarter.
- Cash and cash equivalents were $1.503 million at June 30, 2014, compared with $504,000 a year earlier. Working capital was approximately $8.6 million.
- Accounts receivable declined to $6.487 million from $9.014 million, while inventory increased to $2.235 million from $1.380 million.
- Total debt was approximately $1.297 million, including $1.280 million under a new mortgage term loan and $17,000 of capital lease obligations. No balance was outstanding on the revolving credit line at year-end.
- The company had a $2.5 million revolving credit facility, subject to borrowing-base limitations and scheduled to expire on December 18, 2014 unless renewed.
Material Changes Versus the Prior Comparable Period
- Revenue returned to growth after a 22.6% decline in fiscal 2013. Management attributed the improvement to better reimbursement processes, increased approvals, sales-force enhancements and stronger second-half performance.
- Second-half fiscal 2014 sales increased 34% compared with the first half, and home-care revenue increased 26% between those periods.
- Gross margin weakened modestly because SmartVest SQL had not yet reached full sourcing and manufacturing efficiency. Management expects long-term gross margins to return to approximately 70% as volume increases.
- Operating expenses declined primarily because of lower legal and professional fees, lower marketing and travel costs, and reduced R&D expenses. The company also received $211,000 of insurance reimbursement related to prior shareholder litigation.
- Fiscal 2014 included a $469,000 income-tax expense, including a $454,000 discrete expense from establishing a full valuation allowance against U.S. federal and state deferred tax assets. Excluding this noncash adjustment, management reported an adjusted net loss of approximately $562,000.
- The company refinanced its prior bank debt with Venture Bank, establishing the new revolving facility and a $1.3 million term loan at 5.0%. It also amended the minimum tangible net worth covenant from $12.0 million to $10.125 million.
Guidance, Outlook, Risks and Unusual Items
- Fiscal 2015 priorities include sustainable profitable growth, reducing SmartVest SQL manufacturing costs, improving referral quality and reimbursement rates, enhancing patient support, and increasing sales-team productivity.
- Management plans to focus international resources on existing distributors, with less emphasis on signing new distributors.
- Management believes current working capital and available credit will provide adequate liquidity for the next year and expects to renew the revolving facility, but states that additional financing may not be available on favorable terms, or at all.
- The company violated its tangible net worth covenant during the quarter ended March 31, 2014; the bank waived the default, and the company was compliant at June 30, 2014. Future covenant breaches could permit acceleration of debt, restrict borrowing or prevent renewal of the credit line.
- Revenue depends substantially on Medicare, Medicaid and private-payer reimbursement. Pricing pressure, longer authorization procedures, coverage changes or reduced reimbursement could adversely affect sales, cash flow and covenant compliance.
- Medical-device regulatory compliance, FDA clearances, quality inspections, product liability, intellectual-property protection and international regulatory requirements remain material risks.
- The company recorded a $63,000 charge for abandoned patents covering outdated technology. It also carries a $700,000 warranty reserve, including lifetime warranties for qualifying U.S. home-care systems.
- Estimated unrecognized installment-method sales were $1.908 million at June 30, 2014. Such revenue is recognized as reimbursement installments are collected, creating timing and collectability uncertainty.
- No material litigation was reported; prior shareholder litigation was settled during the first quarter of fiscal 2014. The company reported no off-balance-sheet arrangements.
Investor Verification Checklist
- Verify whether the revolving credit facility was renewed after its December 18, 2014 expiration date and review subsequent covenant compliance.
- Assess SmartVest SQL adoption, manufacturing-cost reductions and whether gross margins improved toward management’s approximately 70% long-term target.
- Review trends in reimbursement approvals, payer coverage, pricing and accounts receivable collections.
- Reconcile reported net loss with management’s adjusted loss excluding the deferred-tax valuation allowance; the adjusted measure is non-GAAP.
- Monitor the realizability of deferred tax assets and any future reversal or adjustment of the $727,000 valuation allowance.
- Evaluate inventory growth, warranty claims and installment-method receivables for potential cash-flow or impairment pressure.
- Review the company’s dependence on a limited HFCWO market, competitive devices, regulatory clearances and patent expirations beginning in 2016.